Tracking how Charcot Marie Tooth disease changes over time
Follows people with several types of Charcot Marie Tooth disease.
Key facts
- Who runs it
- Michael Shy
- Where
- Ann Arbor, Aurora, Baltimore, Boston, Chapel Hill, Columbus, Hartford, Houston, Iowa City, Los Angeles, Memphis, Miami, Minneapolis, Palo Alto, Philadelphia, Rochester, and Seattle, United StatesSee the 18 sitesAlso in 5 other countries, 6 sites
- Trial code
- Registry title
- Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- 1 Apr 2010
- Expected to end
- Dec 2030
- Type of study
- Observational, 5 groups
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with Charcot Marie Tooth disease (CMT), an inherited nerve disease, to follow how it changes over time. People without nerve disease can also join as a comparison group.
- Age
- The record gives no age range. Teenagers aged 13-17 years sign their own assent form.
- Sex
- All sexes can join.
- Disease stage
- Any form of CMT, including CMT1B, CMT2A, CMT4A, CMT4C and forms not yet genetically identified. Comparison volunteers must not have nerve damage in the arms or legs (peripheral neuropathy).
- Biomarker or test result
- Patients need a documented disease-causing gene change linked to CMT, fitting the inheritance pattern. Or a close family member with such a change, plus signs that fit CMT. Some uncertain gene changes can be accepted if judged likely disease-causing.
Main reasons for not taking part
- Patients whose nerve disease has another possible cause and who have no disease-causing gene change
- People who do not sign the consent form
- People the site doctor judges should not take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- General Criteria
- All patients must agree to take part in the study and sign a consent form. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements); Patients:
- Must have a documented, disease-causing variant(s) in a gene with a known or preliminary association with CMT gene as per Strande et al. 2017 AND consistent with the inheritance pattern associated with the genetic subtype (heterozygous in autosomal dominant, biallelic in autosomal recessive, hemizygous males with X-linked)
- OR have a first- or second-degree family member (parent, child, sibling, half-sibling, aunt, uncle, grandparent, or grandchild) with a documented disease-causing variant(s) as above AND a clear link between that family member and the affected patient AND a phenotype consistent with the diagnosis
- In cases where clear links are not available, genetic confirmation is required
- Patients who have a variant(s) of uncertain significance on clinical laboratory reports may still be included if:
- The variant is categorized as pathogenic or likely pathogenic per the "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology." (Richards et al., 2015)
- OR the variant has been found in multiple affected people in a family and has not been found in unaffected family members per "ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classification." (Biesecker et al. 2023)
- OR the principal investigator and the site investigator agree that the variant(s) is (are) likely disease-causing; Controls
- Must not have a peripheral neuropathy, as determined by the site investigator
- Must have understood and signed an IRB approved consent form for the study. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements)
Who cannot take part
- Patient has a different potential cause for their neuropathy AND no disease-causing variant(s)
- Patients:
- Patient does not wish to participate or does not sign a consent form
- Deemed inappropriate by the Site PI
Where in United States
Also in 5 other countries, 6 sites
- University of MichiganAnn Arbor, United StatesContact: Kimberly DuvalTaking people
- University of Colorado HospitalAurora, United StatesContact: Danelle CarterTaking people
- Johns Hopkins UniversityBaltimore, United StatesContact: Simone ThomasTaking people
- Harvard (Massachusetts General Hospital)Boston, United StatesContact: Lauren PoliticaTaking people
- University of North CarolinaChapel Hill, United StatesContact: Caroline SummerourTaking people
- Nationwide Children's HospitalColumbus, United StatesContact: Stephanie DavisTaking people
- University of Connecticut/Connecticut Children's Medical CenterHartford, United StatesContact: Jennifer Twatchtman-Bassett, M.S.Taking people
- Houston Methodist HospitalHouston, United StatesContact: Samia SaadTaking people
- University of IowaIowa City, United StatesContact: Nicole Kressin, MSN, RNTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Youstina MakaryTaking people
- St. Jude Children's Research HospitalMemphis, United StatesContact: Colin Quillivan, MSTaking people
- University of MiamiMiami, United StatesContact: Liuba AlonsoTaking people
- University of MinnesotaMinneapolis, United StatesContact: Mia FreibergTaking people
- Stanford UniversityPalo Alto, United StatesContact: Michelle E JepsenTaking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Sabrina Yum, MDTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Daya StevensTaking people
- University of RochesterRochester, United StatesContact: Janet SowdenTaking people
- Seattle Children's HospitalSeattle, United StatesContact: Shawna Feely, MC, GCTaking people
About the trial
What the trial wants to find out
This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).
Read full original descriptionShow less
The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window
The 5 groups in the trial
- CMT1B
Families/patients with genetically confirmed CMT1B
- CMT2A
Families/patients with genetically confirmed CMT2A
- CMT4A
Families/patients with genetically confirmed CMT4A
- CMT4C
Families/patients with genetically confirmed CMT4C
- All other CMT
Families/patients with all other forms of CMT or CMT that has not yet been genetically identified
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Type (CMT1B), 2A (CMT2A), 4A (CMT4A), 4C (CMT4C), and Others
- Plain-language title
- Tracking how Charcot Marie Tooth disease changes over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Record updated
- 26 October 2026